Atul Bioscience receives EIR report from US FDA

Atul Bioscience Ltd received establishment inspection report (EIR) from the United States Food and Drug Administration (US FDA) for its manufacturing facility situated in Ambernath, Maharashtra.

The EIR was issued post the last inspection of the facility conducted from May 06, 2024, to May 10, 2024 which concluded with zero FDA 483 observations.

The company is engaged in manufacturing and marketing of active pharmaceutical ingredients (APIs), their intermediates and contract manufacturing operations.